Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
OSLO, Norway, May 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological Association ...
OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...
OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder ...
Please provide your email address to receive an email when new articles are posted on . Cystoscopies for recurrent UTIs yield little clinical benefit for patients both with and without high-risk ...
• Evaluation of microhematuria should be risk based; however, patients with a personal or family history of a genetic tumor syndrome involving the kidneys or upper urinary tract should receive upper ...
"Blue Light Cystoscopy Enables Earlier CIS Recognition and Can Guide Risk-Appropriate Management of High-Risk Non–Muscle-Invasive Bladder Cancer: Real-World Outcomes from a U.S. Claims Cohort" by Mark ...
"Upstaging and Risk Migration with BLC for NMIBC: Results from a prospective multicenter registry" by Alireza Ghoreifi, Duke University The study looked at 2,854 NMIBC* patients from the US Blue Light ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results